Luis Miguel Juarez-Salcedo
Overview
Explore the profile of Luis Miguel Juarez-Salcedo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimenez-Sanchez A, Olivares-Guerrero M, Aparicio-Dominguez M, Berenguer-Ruiz S, Juarez-Salcedo L, Munoz-Hernandez P, et al.
Leuk Lymphoma
. 2024 Nov;
66(3):541-547.
PMID: 39540395
No abstract available.
2.
Juarez-Salcedo L, Nimkar S, Corazon A, Dalia S
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062823
Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell...
3.
Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis
Sharda E, Patel R, Juarez-Salcedo L, Dalia S, Hanna C, Gruhonjic H, et al.
Leuk Res
. 2021 May;
108:106615.
PMID: 34052662
Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there...
4.
Conde-Royo D, Juarez-Salcedo L, Dalia S
Drugs Context
. 2020 Oct;
9.
PMID: 33110433
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody-drug...
5.
Juarez-Salcedo L, Conde-Royo D, Quiroz-Cervantes K, Dalia S
Drugs Context
. 2020 May;
9.
PMID: 32426017
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is...
6.
Juarez-Salcedo L, Dalia S
Chin Clin Oncol
. 2020 Feb;
9(6):81.
PMID: 32075392
No abstract available.
7.
Juarez-Salcedo L, Dalia S
Ann Transl Med
. 2020 Feb;
7(Suppl 8):S297.
PMID: 32016016
No abstract available.
8.
Juarez-Salcedo L, Desai V, Dalia S
Drugs Context
. 2019 Oct;
8:212574.
PMID: 31645879
The emergence of targeted therapy for patients with hematological diseases has permanently altered the therapeutic landscape. Immunochemotherapy regimes are now more and more being replaced by targeted therapies due to...
9.
Quiroz-Cervantes K, Juarez-Salcedo L, Nuevo I, Guillen H, Arbeteta J, Golbano N
Br J Haematol
. 2018 Dec;
185(2):206.
PMID: 30592294
No abstract available.
10.
Juarez-Salcedo L, Sokol L, Chavez J, Dalia S
Cancer Control
. 2018 May;
25(1):1073274818778256.
PMID: 29779412
Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT)...